In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Shattuck Labs (STTK – Research Report), with a price target of $28.00. The company’s shares closed yesterday at $2.22.
Pantginis covers the Healthcare sector, focusing on stocks such as Celldex, Panbela Therapeutics, and Onconova Therapeutics. According to TipRanks, Pantginis has an average return of -6.9% and a 32.49% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Shattuck Labs with a $18.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.77 and a one-year low of $1.85. Currently, Shattuck Labs has an average volume of 24.62K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company’s product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
